Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.11/Share
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.29 +3.15%
Revenue Growth %: -49.8%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
MSGM, SMID, VISL, More
Revenue Growth %: -49.8%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.11), versus ($0.05) reported last year. Revenue for the quarter came in at $1.77 million, versus $1.34 million reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- XP Inc. (XP) Tops Q2 EPS by 8c
- CalPrivate Bank names Andra Frazier as chief credit officer
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
